Hospital IT has had KLAS holding vendors accountable for decades. The rest of pharmacy has had vendor marketing. RxSoftwareReport collects verified experiences from the people who actually run these systems — retail independents, compounders, LTC and specialty pharmacies, home infusion, and DME/HME providers — and publishes what the brochures won’t tell you.
Choosing a pharmacy management system is a six-figure decision over the life of a contract — and right now, owners are making it with less information than they’d have buying a delivery van.
A handful of private-equity-backed platforms now control most of pharmacy’s software — community PMS, LTC, specialty, and DME alike. Support quality after an acquisition is the #1 complaint we hear — and nobody measures it.
Several widely used systems have been sunset or end-of-life’d. Thousands of pharmacies must choose a replacement in the next 18 months, mostly on sales demos alone.
Almost every vendor quotes custom pricing. Hidden interface fees, data-export charges, and auto-renewal traps only surface after the contract is signed.
Generic software-review sites hold a few dozen unverified reviews for products running thousands of pharmacies. Nobody verifies the reviewer, and nobody asks the hard questions.
The pharmacy management system is the anchor — but your stack doesn’t stop there, and neither do we. We track 169 systems and counting across the whole pharmacy technology stack. If you run it, you can rate it.
Every major and minor PMS — retail, LTC, specialty, and compounding platforms alike.
Optimization platforms, perpetual-inventory tools, and purchasing marketplaces.
The systems that handle Medicare Part B billing and serialized equipment — a market generic review sites ignore entirely.
Pharmacy-native point of sale and front-end inventory systems.
Split-billing and contract-pharmacy administration (TPAs).
Robotics, vaccine and will-call automation, and DSCSA track-and-trace tools.
Ratings need pharmacies. Capability assessments do not — so those are written and in final review now. Ten category guides covering all 169 systems, each one assessing every vendor against an identical capability list, with summary comparison matrices and the questions to ask in a demo.
From the 62-system Pharmacy Management Systems guide to focused guides on inventory, DME, 340B, POS, automation, compliance and more. $49–$249 each, or $699 for the complete library. Reserve a copy and we’ll email you when they publish.
For any pharmacy changing systems: realistic timelines, what to evaluate by pharmacy type, data conversion explained, contract red flags, and a printable planning worksheet. $399.
The directory and the Market Map stay free, permanently. And if you rate your systems in our survey, we’ll send you any category guide at no charge.
Every price is on the page. No “contact us for pricing,” no negotiation, no vendor-sponsored placement. We criticize a market where nothing has a published price, so we publish ours.
The method is modeled on how the best-respected ratings in hospital health IT are built: verified respondents, structured questions, and publication only in aggregate.
Pharmacy owners, pharmacists-in-charge, and managers rate the systems they run — starting with the PMS, and extending to the inventory, POS, DME, and 340B tools around it: satisfaction, support, value, and whether they’d buy it again. Nothing you wouldn’t say in front of your vendor.
Responses are matched against the national pharmacy registry. No anonymous drive-bys, no vendor employees, no bots — every data point traces to a real, licensed pharmacy.
Respondents who opt in do a 15–20 minute phone conversation covering the things that only surface pharmacist-to-pharmacist: support decay, surprise fees, data-migration war stories.
When a product reaches enough verified responses, its scores publish — overall and by category. Respondents see results first, including how their system compares to the market.
There are places to read about pharmacy software today. None of them were built for the pharmacy signing the contract.
| RxSoftwareReport | Generic review sites | Hospital-IT raters | Vendor content & listicles | |
|---|---|---|---|---|
| Built for | Pharmacy, exclusively — retail independents, compounding, LTC, specialty, infusion, DME/HME | All software, every industry | Hospitals & health systems | Selling you something |
| Reviewers verified as real pharmacies | Yes — matched to the national pharmacy registry | No | Yes (providers) | No reviewers at all |
| Asks what actually matters | Support after acquisitions, contract traps, EDI reliability, migration experience | Generic star ratings | Hospital workflows | Feature checklists |
| Covers your systems | 156 tracked systems: every PMS plus inventory, POS, DME/HME, 340B & automation | A few dozen thin reviews | Not covered | Whoever pays |
| Vendors can pay for placement or leads | Never | Yes — that’s the business model | No | Usually |
| Minimum sample before publishing a score | Yes — published methodology | No | Yes | No data at all |
And the most honest comparison: the best information source in pharmacy today is asking your peers. That’s exactly what this is — verified peer conversations, structured, scored, and published.
RxSoftwareReport is published by Rochol Holdings LLC, trading as NaviRx — an independent research firm focused exclusively on pharmacy. Our team’s background spans pharmacy operations, pharmacy technology, and transaction due diligence — the work of evaluating pharmacy software stacks is what convinced us this resource needed to exist. Full team bios publish with our first scorecards.
We do not — and will not — accept payment, engagements or sponsorship from the software vendors we cover. Read all of our commitments here.
Questions before you take the survey? Send us a note — we read everything and reply quickly, and we’re glad to talk it through on a call if that’s easier.
Right now, we don’t — this phase is about building the dataset. Long-term, the model follows the one proven in hospital IT: published research and benchmark data licensed to the industry, never paid placement. Participation is free for pharmacies, always.
Early access to the results: your system’s scorecard and how it compares to what you could be running — before you renew, before you migrate, before you sign anything.
No. Individual responses are never shared. Published verbatims are stripped of anything identifying. That anonymity is exactly why this data will be more honest than any reference call a vendor arranges.
Yes, if you’re an owner, pharmacist-in-charge, pharmacist, or manager at a U.S. pharmacy of any kind — retail independent, compounding, specialty, long-term care, home infusion, or a DME/HME provider. Community pharmacy is where we started, but every pharmacy’s experience belongs in this data. The pulse survey takes about 5 minutes.
We’re honest about this: we’re early. Data collection began in 2026, and no scorecard publishes until a system crosses its minimum threshold of verified responses — we’d rather publish nothing than publish thin. What we can offer today is the most complete map of the pharmacy technology market anywhere (169 systems and counting), and a promise: respond now and you’ll see every result before the public does.
Once your product has enough verified responses to publish, you’ll get a factual-accuracy review window before anything goes live. Beyond that: encourage your customers to respond. Confident vendors do.
Questions, corrections, licensing, or you’d like to be interviewed for the ratings. We read everything and reply to real questions from real pharmacies.
We’re at the beginning, and that’s the point — the first pharmacies in the data decide what the industry finally gets measured on. Every verified response makes the picture clearer for the next pharmacy facing a renewal, a sunset notice, or a sales demo.
Take the survey